Conference Coverage: SUO 2019 Testicular

Washington, DC (UroToday.com) The clinical utility of current serum tumor markers (alpha-fetoprotein, beta-HCG, and LDH) for testis cancer is limited by the lack of sensitivity and specificity. As such, there is an unmet need in this space for identifying biomarkers that can better guide treatment decision making. Serum microRNAs are candidate biomarkers for diagnosing and monitoring germ cell tumors,^{1, 2} however, the ability of miRNA to inform treatment in low-stage chemotherapy-naïve patients is previously unexplored. 

Non-Accredited

Read Now